CL2014000171A1 - Compuestos derivados de tetrahidropirido-piridina y tetrahidropirido-pirimidina, moduladores de receptores de c5a; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de degeneracion macular relacionada con la edad, retinopatia diabetica, esclerosis multiple, ave, enfermedad de parkinson, enfermedad de crohn, entre otras. - Google Patents

Compuestos derivados de tetrahidropirido-piridina y tetrahidropirido-pirimidina, moduladores de receptores de c5a; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de degeneracion macular relacionada con la edad, retinopatia diabetica, esclerosis multiple, ave, enfermedad de parkinson, enfermedad de crohn, entre otras.

Info

Publication number: CL2014000171A1
Authority: CL; Chile
Prior art keywords: tetrahydropyrid; disease; crohn; parkinson; bird
Prior art date: 2011-07-22

Application number

CL2014000171A

Other languages

English (en)

Inventor

Christine Gelin

Flyer Alec

Michael Adams Christopher

Darsigny Veronique

Brian Hurley Timothy

Ganesh Karki Rajeshri

Ji Nan

Kawanani Toshio

Meredith Erik

H Serrano Wu Michael

Rao Chang

Solovay Catherine

Tien San Lee George

Towler Chrisopher

Har Denis

Bin Hu

Xinglong Jiang

Christina Cappaci-Daniel

Lichun Shen

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-22

Filing date

2014-01-22

Publication date

2014-10-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46604083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000171(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-01-22 Application filed by Novartis Ag filed Critical Novartis Ag

2014-10-03 Publication of CL2014000171A1 publication Critical patent/CL2014000171A1/es

Links

102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 title 1
108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 title 1
208000011231 Crohn disease Diseases 0.000 title 1
206010012689 Diabetic retinopathy Diseases 0.000 title 1
208000018737 Parkinson disease Diseases 0.000 title 1
206010064930 age-related macular degeneration Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
208000002780 macular degeneration Diseases 0.000 title 1
201000006417 multiple sclerosis Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2014000171A 2011-07-22 2014-01-22 Compuestos derivados de tetrahidropirido-piridina y tetrahidropirido-pirimidina, moduladores de receptores de c5a; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de degeneracion macular relacionada con la edad, retinopatia diabetica, esclerosis multiple, ave, enfermedad de parkinson, enfermedad de crohn, entre otras. CL2014000171A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161510643P	2011-07-22	2011-07-22
US201161539732P	2011-09-27	2011-09-27

Publications (1)

Publication Number	Publication Date
CL2014000171A1 true CL2014000171A1 (es)	2014-10-03

Family

ID=46604083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000171A CL2014000171A1 (es)	2011-07-22	2014-01-22	Compuestos derivados de tetrahidropirido-piridina y tetrahidropirido-pirimidina, moduladores de receptores de c5a; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de degeneracion macular relacionada con la edad, retinopatia diabetica, esclerosis multiple, ave, enfermedad de parkinson, enfermedad de crohn, entre otras.

Country Status (26)

Country	Link
US (2)	US8846656B2 (es)
EP (1)	EP2734521B1 (es)
JP (1)	JP6040237B2 (es)
KR (1)	KR20140096020A (es)
CN (1)	CN103814027B (es)
AP (1)	AP2014007398A0 (es)
AR (1)	AR087288A1 (es)
AU (1)	AU2012287183B2 (es)
BR (1)	BR112014001468A2 (es)
CA (1)	CA2842528A1 (es)
CL (1)	CL2014000171A1 (es)
CO (1)	CO6862157A2 (es)
CR (1)	CR20140032A (es)
EA (1)	EA201490320A1 (es)
ES (1)	ES2637167T3 (es)
IL (1)	IL230501A0 (es)
MA (1)	MA35275B1 (es)
MX (1)	MX336497B (es)
PE (1)	PE20141281A1 (es)
PH (1)	PH12014500200A1 (es)
PL (1)	PL2734521T3 (es)
PT (1)	PT2734521T (es)
TN (1)	TN2014000030A1 (es)
TW (1)	TW201311688A (es)
UY (1)	UY34209A (es)
WO (1)	WO2013016197A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2627648A1 (en) *	2010-09-16	2013-08-21	Novartis AG	17aHYDROXYLASE/C17,20-LYASE INHIBITORS
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US8846656B2 (en)	2011-07-22	2014-09-30	Novartis Ag	Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
US9056874B2 (en)	2012-05-04	2015-06-16	Novartis Ag	Complement pathway modulators and uses thereof
PT2855456T (pt) *	2012-05-04	2017-07-10	Novartis Ag	Moduladores da via do complemento e usos dos mesmos
US9611267B2 (en)	2012-06-13	2017-04-04	Incyte Holdings Corporation	Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
US9475806B2 (en)	2013-03-14	2016-10-25	Novartis Ag	Complement factor B inhibitors and uses there of
TWI649318B (zh)	2013-04-19	2019-02-01	英塞特控股公司	作為ｆｇｆｒ抑制劑之雙環雜環
FI3060276T3 (fi)	2013-10-24	2023-06-07		Infuusiojärjestelmä monien lääkkeiden virheellisen kanavoinnin estämiseksi
EP3089963A1 (en)	2013-10-30	2016-11-09	Novartis AG	2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
TWI656121B (zh) *	2014-08-04	2019-04-11	德商拜耳製藥公司	２－（嗎啉－４－基）－１，７－萘啶
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
EP3240537B1 (en)	2014-12-30	2020-09-09	F. Hoffmann-La Roche AG	Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
AU2016219822B2 (en)	2015-02-20	2020-07-09	Incyte Holdings Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3558979B1 (en)	2016-12-22	2021-02-17	Boehringer Ingelheim International GmbH	Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7141130B2 (ja) *	2017-05-31	2022-09-22	ケモセントリックス，インコーポレイティド	Ｃ５ａ阻害剤としての６－５融合環
ES2934507T3 (es) *	2017-05-31	2023-02-22	Chemocentryx Inc	Anillos fusionados en 5-5 como inhibidores de C5a
TWI870922B (zh)	2017-12-21	2025-01-21	德商百靈佳殷格翰國際股份有限公司	作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物
MX2020006460A (es)	2017-12-22	2020-11-06	Chemocentryx Inc	Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
US10828285B2 (en)	2017-12-22	2020-11-10	Chemocentryx, Inc.	Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
EP3737684B1 (en) *	2018-01-10	2022-11-16	Idorsia Pharmaceuticals Ltd	2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases
SG11202009588PA (en)	2018-04-02	2020-10-29	Chemocentryx Inc	PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
ES2991427T3 (es)	2018-05-04	2024-12-03	Incyte Corp	Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
TW201946630A (zh)	2018-05-04	2019-12-16	美商英塞特公司	Fgfr抑制劑之鹽
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
GEAP202415945A (en)	2019-10-14	2024-04-25	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en)	2019-12-04	2022-06-02	Incyte Corporation	Derivatives of an FGFR inhibitor
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
MX2022010040A (es) *	2020-02-17	2022-09-05	Alesta Therapeutics BV	Compuestos moduladores de gcn2.
KR20250057919A (ko) *	2020-04-29	2025-04-29	릴레이 테라퓨틱스, 인크.	PI3Kα 억제제 및 이의 사용 방법
US20230357239A1 (en)	2020-09-18	2023-11-09	Bayer Aktiengesellschaft	Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
WO2022092247A1 (ja) *	2020-10-30	2022-05-05	第一三共株式会社	３－メチル－４－ハロ－インドール誘導体の製造方法
GB202104286D0 (en) *	2021-03-26	2021-05-12	Syngenta Crop Protection Ag	Chemical process
EP4323405A1 (en)	2021-04-12	2024-02-21	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4074317A1 (en)	2021-04-14	2022-10-19	Bayer AG	Phosphorus derivatives as novel sos1 inhibitors
AR126101A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
CN117820340A (zh) *	2022-12-01	2024-04-05	成都硕德药业有限公司	Atr抑制剂及其用途
KR20250000614A (ko) *	2023-06-27	2025-01-03	서울대학교병원	신규한 망막질환 예방 또는 치료용 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT72878B (en)	1980-04-24	1983-03-29	Merck & Co Inc	Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4727149A (en)	1982-03-11	1988-02-23	John Wyeth & Brother Limited	Preparation of nitriles of fused ring pyridine derivatives
US5853740A (en)	1996-08-07	1998-12-29	Abbott Laboratories	Delivery system for pharmaceutical agents encapsulated with oils
DK1318997T3 (da)	2000-09-15	2006-09-25	Vertex Pharma	Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
AU2003253130A1 (en)	2002-08-19	2004-03-03	Glenmark Pharmaceuticals Limited	Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
CA2514733A1 (en)	2003-02-28	2004-09-16	Transform Pharmaceuticals, Inc.	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004087056A2 (en)	2003-03-28	2004-10-14	Scios Inc.	BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
BRPI0409211A (pt)	2003-04-18	2006-03-28	Lilly Co Eli	composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
AR045445A1 (es) *	2003-08-05	2005-10-26	Vertex Pharma	Compuestos ihinibidores de canales ionicos regulados por voltaje
GB0403038D0 (en)	2004-02-11	2004-03-17	Novartis Ag	Organic compounds
TW200608976A (en)	2004-05-08	2006-03-16	Neurogen Corp	4,5-disubstituted-2-aryl pyrimidines
US7429666B2 (en)	2004-06-10	2008-09-30	Merck Frosst Canada Ltd.	Pyridine analogs as C5a antagonists
JP5046942B2 (ja)	2004-09-30	2012-10-10	テイボテク・フアーマシユーチカルズ	Ｈｃｖ阻害性の二環式ピリミジン類
EP1915373B1 (en)	2005-08-12	2013-05-22	Merck Sharp & Dohme Corp.	Heterobicyclic compounds useful as p38 kinase inhibiting agents
BRPI0710512A2 (pt)	2006-04-20	2012-06-05	Hoffmann La Roche	moduladores derivados de diazepan de receptores de quimiocinas
JP2009534454A (ja)	2006-04-25	2009-09-24	アステックス、セラピューティックス、リミテッド	医薬化合物
US8563566B2 (en)	2007-08-01	2013-10-22	Valeant Pharmaceuticals International	Naphthyridine derivatives as potassium channel modulators
WO2009023669A1 (en)	2007-08-13	2009-02-19	Janssen Pharmaceutica N.V.	Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof
UA101676C2 (uk)	2008-07-31	2013-04-25	Дженентек, Инк.	Піримідинові сполуки, композиції і способи застосування
WO2010028174A1 (en)	2008-09-03	2010-03-11	Dr. Reddy's Laboratories Ltd.	Novel biccyclic compounds as gata modulators
AR073304A1 (es)	2008-09-22	2010-10-28	Jerini Ag	Moduladores del receptor de bradiquinina b2 de molecula pequena
WO2010120994A2 (en)	2009-04-17	2010-10-21	Wyeth Llc	Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
EP2424556A4 (en)	2009-04-27	2013-07-31	Jerini Ophthalmic Inc	EXTENDED RELEASE FORMULATIONS OF PEPTIDOMIMETIC MEDICAMENTS AND USES THEREOF
WO2010138430A1 (en)	2009-05-27	2010-12-02	Merck Sharp & Dohme Corp.	Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors
WO2011022213A1 (en)	2009-08-17	2011-02-24	Merck Sharp & Dohme Corp.	Amino tetrahydro-pyridopyrimidine pde10 inhibitors
JP2013032290A (ja)	2009-11-20	2013-02-14	Dainippon Sumitomo Pharma Co Ltd	新規縮合ピリミジン誘導体
US8846656B2 (en)	2011-07-22	2014-09-30	Novartis Ag	Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
US20140227321A1 (en)	2011-09-30	2014-08-14	Kineta, Inc.	Anti-viral compounds
WO2013082535A2 (en)	2011-12-02	2013-06-06	Board Of Regents Of The University Of Nebraska	Controlled-release peptide compositions and uses thereof

2012
- 2012-07-19 US US13/553,120 patent/US8846656B2/en not_active Expired - Fee Related
- 2012-07-20 BR BR112014001468A patent/BR112014001468A2/pt not_active Application Discontinuation
- 2012-07-20 PT PT127430239T patent/PT2734521T/pt unknown
- 2012-07-20 PL PL12743023T patent/PL2734521T3/pl unknown
- 2012-07-20 KR KR1020147004232A patent/KR20140096020A/ko not_active Ceased
- 2012-07-20 UY UY0001034209A patent/UY34209A/es not_active Application Discontinuation
- 2012-07-20 JP JP2014521829A patent/JP6040237B2/ja not_active Expired - Fee Related
- 2012-07-20 CN CN201280045758.6A patent/CN103814027B/zh not_active Expired - Fee Related
- 2012-07-20 EP EP12743023.9A patent/EP2734521B1/en active Active
- 2012-07-20 WO PCT/US2012/047617 patent/WO2013016197A1/en not_active Ceased
- 2012-07-20 PE PE2014000114A patent/PE20141281A1/es not_active Application Discontinuation
- 2012-07-20 AP AP2014007398A patent/AP2014007398A0/xx unknown
- 2012-07-20 EA EA201490320A patent/EA201490320A1/ru unknown
- 2012-07-20 ES ES12743023T patent/ES2637167T3/es active Active
- 2012-07-20 MX MX2014000898A patent/MX336497B/es unknown
- 2012-07-20 TW TW101126407A patent/TW201311688A/zh unknown
- 2012-07-20 CA CA2842528A patent/CA2842528A1/en not_active Abandoned
- 2012-07-20 PH PH1/2014/500200A patent/PH12014500200A1/en unknown
- 2012-07-20 AU AU2012287183A patent/AU2012287183B2/en not_active Ceased
- 2012-07-23 AR ARP120102669A patent/AR087288A1/es unknown
2014
- 2014-01-16 IL IL230501A patent/IL230501A0/en unknown
- 2014-01-20 MA MA36696A patent/MA35275B1/fr unknown
- 2014-01-20 TN TNP2014000030A patent/TN2014000030A1/en unknown
- 2014-01-22 CL CL2014000171A patent/CL2014000171A1/es unknown
- 2014-01-22 CR CR20140032A patent/CR20140032A/es unknown
- 2014-01-24 CO CO14014580A patent/CO6862157A2/es active IP Right Grant
- 2014-08-08 US US14/455,848 patent/US9505755B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20130184253A1 (en)	2013-07-18
CN103814027B (zh)	2016-07-06
JP6040237B2 (ja)	2016-12-07
IL230501A0 (en)	2014-03-31
CN103814027A (zh)	2014-05-21
US8846656B2 (en)	2014-09-30
TN2014000030A1 (en)	2015-07-01
MX336497B (es)	2016-01-21
PT2734521T (pt)	2017-08-11
AU2012287183B2 (en)	2014-11-20
UY34209A (es)	2013-02-28
US9505755B2 (en)	2016-11-29
PH12014500200A1 (en)	2014-03-03
US20140349995A1 (en)	2014-11-27
BR112014001468A2 (pt)	2017-01-10
EP2734521B1 (en)	2017-05-10
CR20140032A (es)	2014-05-16
EA201490320A1 (ru)	2014-06-30
WO2013016197A1 (en)	2013-01-31
KR20140096020A (ko)	2014-08-04
CA2842528A1 (en)	2013-01-31
AU2012287183A1 (en)	2014-01-30
PL2734521T3 (pl)	2017-10-31
EP2734521A1 (en)	2014-05-28
ES2637167T3 (es)	2017-10-11
MA35275B1 (fr)	2014-07-03
AP2014007398A0 (en)	2014-01-31
JP2014521607A (ja)	2014-08-28
AR087288A1 (es)	2014-03-12
CO6862157A2 (es)	2014-02-10
MX2014000898A (es)	2014-02-19
TW201311688A (zh)	2013-03-16
PE20141281A1 (es)	2014-09-24

Publication	Publication Date	Title
CL2014000171A1 (es)	2014-10-03	Compuestos derivados de tetrahidropirido-piridina y tetrahidropirido-pirimidina, moduladores de receptores de c5a; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de degeneracion macular relacionada con la edad, retinopatia diabetica, esclerosis multiple, ave, enfermedad de parkinson, enfermedad de crohn, entre otras.
CL2014001752A1 (es)	2014-10-10	Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
PH12014501351A1 (en)	2014-09-22	Fluorinated estrogen receptor modulators and uses thereof
CL2013002474A1 (es)	2014-05-30	Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras.
CL2014000956A1 (es)	2014-07-18	Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
CL2015000295A1 (es)	2015-04-24	Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
DOP2016000226A (es)	2016-10-31	Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CL2014000032A1 (es)	2014-08-01	Compuestos derivados de bencilamina, inhibidores de calicreina plasmatica; composicion farmaceutica; y su uso para el tratamiento de agudeza visual deteriorada, retinopatia diabetica, edema macular diabetico, hipotension cardiomiopatia, cancer, entre otros
CL2013001964A1 (es)	2013-11-29	Compuestos derivados de heterociclos, como inhibidores de bace 1 o 2; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento o prevencion de la enfermedad de alzheimer o deterioro cognitivo leve, resistencia a la insulina, diabetes tipo 2, entre otras.
PH12014502095A1 (en)	2014-11-24	Estrogen receptor modulators and uses thereof
CL2014000806A1 (es)	2014-09-05	Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
CL2014002093A1 (es)	2014-11-21	Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2012003604A1 (es)	2013-03-22	Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
CL2013002053A1 (es)	2013-11-29	Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CL2008003120A1 (es)	2009-10-09	Compuestos derivados de fenilalquil-, fenilalquenil-, fenilalquinil- amina, feniltioalquilamina, fenilaminoalquilamina, fenilalcoxiamina y fenilalquilguanidina; composicion farmaceutica; y uso de los compuestos para tratar un trastorno o enfermedad oftalmologica tal como retinopatia, maculopatia, retinitis pigmentosa, uveitis, entre otras.
AR090491A1 (es)	2014-11-19	Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
CL2014001060A1 (es)	2014-11-07	Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
MX377410B (es)	2025-03-10	Antagonistas de receptores de integrina y sus metodos de uso.
CL2014001047A1 (es)	2014-11-07	Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
DOP2016000212A (es)	2016-11-15	Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
ECSP11010956A (es)	2011-05-31	Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
UY35276A (es)	2014-08-29	Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2014003429A1 (es)	2015-03-27	Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
CL2015000891A1 (es)	2015-09-11	Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras.
CL2013002424A1 (es)	2014-03-28	Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras.